Blood eosinophils as a marker of CVD in COPD patients

Résumé fourni par la source

Background Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by chronic respiratory symptoms and airflow limitation. Comorbidities, especially cardiovascular disease (CVD), are known to have a significant impact on its prognosis. Aim Assess whether the presence of high level of blood eosinophils (HBEC ≥300 cell/uL) in COPD may be associated with a different disease control, lung function and CVD comorbidities prevalence compared to COPD patients with low BEC (LBEC). Methods COPD patients were retrospectically evaluated and divided in two groups according to BEC < or ≥300 cell/uL. The analysed variables were comorbidities, smoking habits, blood eosinophils and neutrophils, 6-minute walking test (6MWT), arterial blood gas (ABG) values, systolic pulmonary artery pressure (PASP), number of exacerbations in the previous year and pulmonary functionality. A p-value of less than 0.05 was considered statistically significant. Results Out of 196 patients enrolled, 43 (21.9%) have HBEC COPD patients with HBEC had higher CVD (p=0.024) and bronchiectasis (p= 0.038) prevalence than patients with LBEC. In addition, the presence of HBEC is linked with ischemic heart disease (OR:3.4; 1.68–6.89, p=0.001). This association was not influenced by smoking habits (p = 0.899) and body mass index (p = 0.912). Moreover, patients with HBEC had a higher number of exacerbations in the previous year (p=0.041). Lung function variables, CAT and 6MWTwere not different in the two groups. Conclusion: Our results suggest that HBEC could be used as biomarkers to better phenotype COPD patients with CVD. More studies are needed.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.